Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

BACKGROUND: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-...

Full description

Saved in:
Bibliographic Details
Main Authors: Thompson Coon, J S, Liu, Z, Hoyle, M, Rogers, G, Green, C, Moxham, T, Welch, K, Stein, K
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2009
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720220/
https://ncbi.nlm.nih.gov/pubmed/19568242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605167
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items